Sean Tristan Cook, DO
Infectious Disease · Coeur D Alene, IDNPI 1083811475
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Insmed, Inc. accounts for 96.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $16,253 and has fallen 99.8% since, to $26 in 2025. Among infectious disease clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $293.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$31K
- AbbVie$270
- Gilead$225
- Merck$144
- Shionogi Inc$122
- Amgen$120
- plus $265 from 8 others
Across 86 payments — averaging $2518.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$217K
What the payments were for
- Consulting fees$8,79027%
- Speaking & faculty fees$18,93059%
- Travel & lodging$1,9696%
- Food & beverage$2,0907%
- Education$2641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 52 | $30,897 |
| AbbVie(2 entities) | 15 | $270 |
| Gilead | 11 | $225 |
| Merck | 9 | $144 |
| Shionogi Inc | 2 | $122 |
| Amgen | 6 | $120 |
| Melinta Therapeutics, LLC | 4 | $66 |
| Organogenesis Inc. | 3 | $53 |
| Astellas Pharma US Inc | 2 | $48 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $22 |
| Convatec Inc. | 1 | $21 |
| Solventum Corporation | 1 | $21 |
| Medtronic | 1 | $18 |
| KCI USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,043 in reported general payments places this provider in the 95th percentile of 29 infectious disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 19 | $290,062 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 38 | $146,237 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 25 | $97,135 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $89,759 |
| JulucaDolutegravir/Rilpivirine | 24 | $80,724 |
| IsentressRaltegravir Potassium | 12 | $22,720 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 12 | $15,361 |
| Cephalexin | 108 | $6,128 |
| Cefazolin Sodium | 64 | $3,712 |
| Vancomycin Hcl | 19 | $3,218 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 22 | $1,650 |
| Fluconazole | 27 | $1,564 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 53 | $1,344 |
| CeftriaxoneCeftriaxone Sodium | 24 | $1,275 |
| Ethambutol Hcl | 19 | $980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $30,897 | $290,06219 claims |
| GileadGenvoya, Biktarvy | $225 | $235,99661 claims |
| MerckIsentress | $144 | $22,72012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 29 infectious disease providers in Idaho.
Other infectious disease in Coeur D Alene
- Melanie EnderwickCoeur D Alene$172
- David SouvenirCoeur D Alene$14
- Richard NathanIdaho Falls$5K
- Sky BlueBoise$2K
- Thomas CoffmanBoise$838
- Sarah ShewayishBoise$769
- Quentin DoperalskiBoise$516
- John HammerBoise$389
- Sharon OsterBoise$327
- Jonathan SalbergBoise$265
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.